Jiangsu Yong'an Pharmaceutical Co Ltd.

Main study objectives: To investigate the relative bioavailability of a single oral (fasting/postprandial) test formulation of sacubitril-valsartan sodium tablets [Specification: 200 mg (sacubitril 97 mg/valsartan 103 mg), produced by Jiangsu Yongan Pharmaceutical Co., Ltd.] and a reference formulation [Trade name: Nusintuo, Specification: 200 mg (sacubitril 97 mg/valsartan 103 mg), produced by Novartis Farma S.p.A.] in healthy Chinese subjects, analyze the pharmacokinetic parameters of the two formulations, evaluate the bioequivalence of the two formulations, and provide a reference for the application and clinical use of the drug. Secondary study objectives: To evaluate the safety of a single oral (fasting/postprandial) test formulation and reference formulation in healthy adult Chinese subjects.

The main purpose of the study is to investigate the relative bioavailability of the test preparation Iguratimod tablets (specification: 25 mg, produced by Jiangsu Yongan Pharmaceutical Co., Ltd.) and the reference preparation Iguratimod tablets (trade name: Edesin®, specification: 25 mg, produced by Hainan Xiansheng Pharmaceutical Co., Ltd. with a license) in healthy Chinese subjects after a single oral dose (fasting/postprandial), analyze the pharmacokinetic parameters of the two preparations, evaluate the bioequivalence of the two preparations, and provide a reference for the application and clinical use of the test preparation Iguratimod tablets. The secondary purpose of the study is to evaluate the safety of the test preparation and the reference preparation in Chinese healthy adult subjects after a single oral dose (fasting/postprandial).

Main study objectives: To investigate the relative bioavailability of the test preparation Cinipride Tartrate Tablets (Specification: 1 mg, produced by Jiangsu Yongan Pharmaceutical Co., Ltd.) and the reference preparation Cinipride Tartrate Tablets (trade name: Cidine®, specification: 1 mg, licensed by Almirall, S.A.) in healthy Chinese adults after a single oral administration on an empty stomach/after a meal, analyze the pharmacokinetic parameters of the two preparations, and evaluate the bioequivalence of the two preparations. Secondary study objectives: To evaluate the safety of the test preparation and the reference preparation in healthy Chinese adults after a single oral administration on an empty stomach/after a meal.